Frontiers in Cancer Immunotherapy

Day 1: February 27, 2017

7:45 AM

Breakfast and Registration

8:30 AM

Introduction and Welcome Remarks
Angela Colmone, PhD, representing Science, Science Translational Medicine, and Science Immunology
Melanie Brickman Borchard, PhD, MSc, The New York Academy of Sciences

8:55 AM

Keynote Address:
From the Clinic to the Lab: Investigating Response and Resistance Mechanisms to Immune Checkpoint Therapy
Padmanee Sharma, MD, PhD, The University of Texas MD Anderson Cancer Center

Session 1: Assessment of Current Therapeutic Approaches in Cancer Immunotherapy: Successes and Challenges

Session Chair: Jedd D. Wolchok, MD, Memorial Sloan Kettering Cancer Center

9:40 AM

Engineering T Cells to Be Effective in Tumor Therapy
Philip D. Greenberg, MD, University of Washington

10:05 AM

Modulation of Immunity through Dendritic Cell Targeting
Nina Bhardwaj, MD, PhD, Mount Sinai School of Medicine

10:30 AM

Treating the Tumor and Treating the Host
Ronald Levy, MD, Stanford University

10:55 AM

Networking Coffee Break

Session 2: Evaluation of Combination Therapy Strategies to Improve Clinical Outcomes

Session Chair: Michele Maio, PhD, University Hospital, Sienna

11:25 AM

Immunologic Checkpoint Blockade: Exploring Combinations and Mechanisms
Jedd D. Wolchok, MD, Memorial Sloan Kettering Cancer Center

11:50 AM

The Promise of Epigenetic Therapies for Enhancing the Efficacy of Immune Checkpoint Therapy
Stephen B. Baylin, MD, Johns Hopkins University

12:15 PM

Therapeutic Vaccination for Premalignant HPV Disease: It's Getting Better All the Time
Cornelia (Connie) Liu Trimble, MD, Johns Hopkins University

12:40 PM

Networking Lunch and Poster Viewing

12:55 PM

Underrepresented Minorities, Women, and Early Career Investigator Career Development Workshop and Lunch Running Concurrently with the Networking Lunch 
For Graduate Students, Post-doctoral Fellows, and Junior Faculty

Editor's Guide to Writing and Publishing Your Paper
Angela Colmone, PhD, Editor, Science Immunology
Priscilla Kelly, PhD, Associate Editor, Science
Yevgeniya Nusinovich, MD, PhD, Senior Editor, Science Translational Medicine

Session 3: Identification of Relevant Prognostic and Predictive Biomarkers for the Development of Immune-Monitoring Strategies

Session Chair: Angela Colmone, PhD, Science Immunology

2:00 PM

Inflammation and Cancer: Fueling Response and Resistance of Immunotherapies
Lisa Coussens, PhD, Oregon Health Sciences University

2:25 PM

T cell Receptor Responses in Health and Disease
Mark Davis, PhD, Stanford University

2:50 PM

Melanoma Response and Resistance to PD-1 Blockade Therapy
Antoni Ribas, MD, PhD, University of California Los Angeles

3:15 PM

Networking Coffee Break

Session 4: Development of Strategies to Overcome Immune Tolerance

Session Chair: Kunle Odunsi, MD, PhD, Roswell Park Cancer Institute

3:40 PM

Tumor and Host Pathways that Shape Degrees of Immunotherapy Resistance
Thomas Gajewski, MD, PhD, University of Chicago

4:05 PM

Molecular and Epigenetic Programs Underlying CD8 T Cell Dysfunction in Solid Tumors
Andrea Schietinger, PhD, Memorial Sloan Kettering Cancer Center

4:30 PM

Targeting FoxP3+ T-cells in Cancers; Friends or Foes?
Hiroyoshi Nishikawa, MD, PhD, National Cancer Center Hospital, Japan

4:55 PM

Emerging Technologies in Cancer Immunotherapy
Carl June, MD, University of Pennsylvania

5:20 PM

Panel Discussion — Day 1 Wrap-up 
Moderator: Yevgeniya Nusinovich, MD, PhD, Science Translational Medicine
 
Panelists:

Philip D. Greenberg, MD, University of Washington
Connie Trimble, MD, Johns Hopkins University
Mark Davis, PhD, Stanford University
Carl June, MD, University of Pennsylvania

5:45 PM

Closing Remarks

5:55 PM

Poster Session 1 and Networking Reception

7:00 PM

Day 1 Adjourns

Day 2: February 28, 2017

8:00 AM

Breakfast and Registration

8:00 AM

Underrepresented Minorities, Women, and Early Career Investigator Mentoring Breakfast Running Concurrently with the General Breakfast

Mentors:
•   Stephen B. Baylin, MD, Johns Hopkins University
•   Michele Maio, PhD, University Hospital, Sienna
•   Crystal Mackall, MD, Stanford University

Session 5: Clinical Research Break Out Sessions

9:00 AM

Breakout Group 1: How to Manage Toxicities in Cancer Immunotherapy?
Jedd D. Wolchok, MD, PhD, Memorial Sloan Kettering Cancer Center

Breakout Group 2: How to Incorporate Biomarkers into Early Phase Immunotherapy Trials?
Kunle Odunsi, MD, PhD, Roswell Park Cancer Institute
Sacha Gnjatic, PhD, Mount Sinai School of Medicine

Breakout Group 3: What are the Latest Strategies for Cancer Immunotherapy Development — a Pharmaceutical Industry Perspective?
Ira Mellman, PhD, Genentech

10:00 AM

Networking Coffee Break

Session 6: Optimizing Incorporation of Cancer Genomics and Epigenomics into Immunotherapy Research and Clinical Strategies

Session Chair: Laurence Zitvogel, MD, PhD, Institut National de la Santé et Recherche Médicale

10:30 AM

T-cell Adoptive Therapy Moves Beyond Melanoma
James C. Yang, MD, National Cancer Institute, U.S. National Institutes of Health

10:55 AM

Epigenetic Immunomodeling for Cancer Immunotherapy
Michele Maio, PhD, University Hospital, Sienna

11:20 AM

Immunotherapeutic Responses to Cancer Neoantigens
Matthew Gubin, PhD, Washington University

11:45 AM

Networking Lunch and Poster Session 2

Session 7: Targeting T-cells in Cancer Immunotherapy

Session Chair: Philip D. Greenberg, MD, University of Washington

1:15 PM

Regulatory T-cells and Strategies for Inhibition for Cancer Therapy
Alexander Rudensky, PhD, Memorial Sloan Kettering Cancer Center

1:40 PM

Chimeric Antigen Receptors: Progress and Challenges
Crystal Mackall, MD, Stanford University

2:05 PM

Targeting Tryptophan Metabolism to Overcome Negative Regulation of Antitumor Immunity in Ovarian Cancer
Kunle Odunsi, MD, PhD, Roswell Park Cancer Institute

2:30 PM

Networking Coffee Break

Session 8: Hot Topic Short Talks

Session Chair: Hiroyoshi Nishikawa, MD, PhD, National Cancer Center Hospital, Japan

3:00 PM

Activating the Brain to Fight Cancer: Reward System Activation Attenuates Tumor Growth in Mice
Tamar Ben-Shaanan, MsC, Technion, Israel Institute of Technology

3:15 PM

MEX3B Mediates Resistance to T cell-based Immunotherapy by Impairing Antigen Processing and Presentation
Lu Huang, PhD, The University of Texas M.D. Anderson Cancer Center

3:30 PM

Fatty Acid Metabolism Limits an Oxidative Stress Response that Promotes T Cell Exhaustion During Rapid Clonal Proliferation
Roddy O'Connor, University of Pennsylvania

3:45 PM

Tissue-specific Efficacy and Safety of Checkpoint Blockade Combination Immunotherapy
Kavya Rakhra, PhD, Massachusetts Institute of Technology

4:00 PM

Inducing New Systemic Immune Responses and Frequent Durable Complete Regressions (CRs) of Human Metastatic Melanoma with Intralesional Secreted Cytokines
Fred T. Valentine, MD, New York University School of Medicine

Session 9: Emerging Technologies in Cancer Immunotherapy

Session Chair: Melanie Brickman Borchard, PhD, MSc, The New York Academy of Sciences

4:15 PM

Role of the Human Intestinal Microbiome in the Response to PD1 Blockade in Advanced Cancer
Laurence Zitvogel, MD, PhD, Institut National de la Santé et Recherche Médicale

4:40 PM

Closing Remarks

4:50 PM

Conference Adjourns

Conrad New York

212.945.0100

Millenium Hilton

212.693.2001

Marriott Financial Center

212.385.4900

Club Quarters, Wall Street

212.269.6400

Eurostars Wall Street Hotel

212.742.0003

Gild Hall, Financial District

212.232.7700

Wall Street Inn

212.747.1500

Ritz-Carlton New York, Battery Park

212.344.0800